HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-4889

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy ; volume:13 ; number:11 ; day:18 ; month:11 ; year:2022 ; pages:1-15 ; date:11.2022
Cell death & disease ; 13, Heft 11 (18.11.2022), 1-15, 11.2022

Creator: Cristofani, Riccardo
Piccolella, Margherita
Montagnani Marelli, Marina
Tedesco, Barbara
Poletti, Angelo
Moretti, Roberta Manuela

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41419-022-05365-9

URN: urn:nbn:de:101:1-2023013121094426424496

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:39 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cristofani, Riccardo
Piccolella, Margherita
Montagnani Marelli, Marina
Tedesco, Barbara
Poletti, Angelo
Moretti, Roberta Manuela
SpringerLink (Online service)

Other Objects (12)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Hochschulschrift

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

$Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma$

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Induction of N-Ras degradation by flunarizine-mediated autophagy

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

$Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma$

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Hochschulschrift

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

$Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma$

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Induction of N-Ras degradation by flunarizine-mediated autophagy

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

$Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma$

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Hochschulschrift

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

$Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma$

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Induction of N-Ras degradation by flunarizine-mediated autophagy

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

$Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma$

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

MEK targeting in N-RAS mutated metastatic melanoma

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Induction of N-Ras degradation by flunarizine-mediated autophagy

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

MEK targeting in N-RAS mutated metastatic melanoma

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Induction of N-Ras degradation by flunarizine-mediated autophagy

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

MEK targeting in N-RAS mutated metastatic melanoma

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Induction of N-Ras degradation by flunarizine-mediated autophagy

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Related objects

Reset password